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Endometrial polyps exceeding 4 centimeters in length are exceedingly rare and are termed “giant polyps.” We describe two patients
that presented to our hospital with giant endometrial polyps. Clinical implications and oncologic potential of giant endometrial
polyps are discussed. Risk factors of oncologic transformation include advanced age, menopausal status, obesity, diabetes, arterial
hypertension, use of tamoxifen, and size greater than 1.0 centimeter. A literature review of all documented cases of giant endometrial
polyps is presented and management strategies for counseling and polypectomy are reviewed.

1. Introduction
Endometrial polyps are localized overgrowths of the endometrial lining of the uterus. Microscopically, they are composed
of varying amounts of glandular tissue, stroma, and blood
vessels covered by an epithelium. Their size can range from a
few millimeters to beyond 5 centimeters in length. Endometrial polyps larger than 1 cm are termed “large polyps,” and
those that are greater than 4 cm, which are exceedingly rare,
are called “giant polyps” [1].
The exact incidence of endometrial polyps is unknown;
however, in women with dysfunctional uterine bleeding,
the prevalence of endometrial polyps ranges from 10% to
24% [2]. 10% to 25% of symptomatic polyps may contain
hyperplastic foci and malignant transformation has been
observed in about 0 to 12.9% [2]. Although evidence in the
literature defining factors linked to malignant transformation
is contradictory, advanced age, menopausal status, obesity,
diabetes, arterial hypertension, and use of tamoxifen have
reached statistical significance in varying reports [3–5]. Additionally, polyp size has been found to be a predictive factor.
B. P. Lasmar and R. B. Lasmar [6] found that endometrial
polyps larger than 1.5 cm were associated with hyperplasia,
while a separate report by Wang et al. [3] identified that

polyps measuring more than 1.0 cm were associated with
malignancy.
We describe two patients that presented to our hospital
with giant endometrial polyps and present a literature review
of other similar cases. The oncogenic potential of large polyps
is evaluated and evidence-based management strategies are
discussed.

2. Case Series
2.1. Case #1. FM is a 70-year-old postmenopausal black
female who presented with a chief complaint of intermittent
vaginal spotting since the age of 50. She had not sought
gynecologic care for several years. FM reported two episodes
of vaginal spotting over the previous year, each lasting
approximately one week in duration. Otherwise, she was
asymptomatic and denied any recent intercourse or trauma
to the vaginal area. Her past medical history was significant
for poorly controlled hypertension, poorly controlled type
2 diabetes mellitus, osteoarthritis, angina, vitamin D deficiency, and glaucoma. She reported a long history of normal
Pap smears over the course of her life and had one fullterm normal spontaneous vaginal delivery. Family history
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Figure 1: Ultrasound imaging of uterus demonstrating a 12.1 mm endometrial stripe.

Figure 2: Gross specimen of polyp from case #1.

was significant for breast cancer in her mother at the age of 60
years. She denied any family history of uterine cancer, colon
cancer, or ovarian cancer.
On initial evaluation, FM was alert and oriented and
well nourished, with a body mass index (BMI) of 28 kg/m2 .
On physical examination, her vaginal mucosa was atrophic.
A 1 cm polyp that originated from the endometrial cavity
was found to be protruding from the cervical os and was
friable to the touch. On bimanual exam, the uterus was
anteverted, smooth, and mobile without palpable adnexal
masses. Transvaginal ultrasound confirmed an anteverted
uterus measuring 9.1×5.2×7.1 cm with a thickened, heterogeneous endometrial echo measuring 12.1 mm with multiple
cystic small spaces (Figure 1). A vascular signal was seen
throughout the thickened endometrium and a partially calcified leiomyoma in the left uterine body was also noted. An
endometrial biopsy was obtained and showed rare superficial fragments of inactive endometrial tissue. Due to postmenopausal bleeding, the patient was booked for operative
hysteroscopy, dilation and curettage, and polypectomy. On
hysteroscopy, a large polyp was seen arising from the anterior
uterine wall. Using operative hysteroscopy and hysteroscopic
scissors, this polyp, measuring 5.3 cm in greatest dimension,
was removed in its entirety (Figure 2). Endometrial curettage
was performed after complete removal of the polyp. Final
pathology showed inactive endometrium without evidence of
hyperplasia (Figure 3). At the two-week postoperative visit,
FM reported complete resolution of her symptoms.

Figure 3: Microscopic section of polyp from case #1. H&E stain,
demonstrating inactive endometrium, few glands, fibrotic stroma,
and dilated, thick-walled blood vessels.

2.2. Case #2. HA is a 66-year-old obese postmenopausal
Hispanic female who presented with a chief complaint of
intermittent vaginal spotting of a duration of eight months.
Past medical history was significant for poorly controlled
hypertension, aortic stenosis, hypercholesterolemia, and
glaucoma. She reported a history of normal Pap smears
throughout her life, the last one being one month prior to
presentation. She had two full-term vaginal deliveries and one
cesarean delivery. HA denied any significant family history
of malignancy. On initial examination, she was noted to be
alert and oriented and was obese with a BMI of 39.5 kg/m2 .
The external genitalia appeared normal and without lesions.
A polyp was seen protruding 2 cm from the cervical os.
On bimanual exam, the uterus was noted to be mobile,
anteverted, and smooth, with no palpable adnexal masses.
Transvaginal ultrasound revealed a 9.6 × 5.9 × 5.7 cm uterus
with endometrial lining measuring 20 mm with small cystic
appearing areas (Figure 4). Due to the large polyp protruding
from the cervical os, the patient was booked for operative
hysteroscopy, dilation and curettage, and polypectomy. The
polyp was grasped with forceps and removed from its base
prior to the hysteroscope being introduced to the uterine
cavity. The polyp measured 8 cm in its greatest dimension.
Hysteroscopy revealed areas of polypoid tissue which were
removed under direct visualization (Figure 5). Endometrial
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Figure 4: Ultrasound imaging of uterus demonstrating endometrial lining measuring 20 mm containing small cystic appearing areas.

Figure 5: Gross specimen of polyp from case #2.

Figure 6: Microscopic section of polyp from case #2. H&E stain, low-power photomicrographs showing intact polypoid tissue cystic dilated
glands without evidence of hyperplasia, fibrotic stroma, and dilated thick-walled vessels.

curettage was then performed. Final pathology revealed inactive endometrium with no hyperplasia or atypia (Figure 6). At
her two-week postoperative visit, she reported a resolution of
her symptoms.

3. Discussion
Endometrial polyps are found in both premenopausal and
postmenopausal women. Patients may either be asymptomatic at the time of diagnosis or present with abnormal bleeding patterns, including intermenstrual bleeding,
menorrhagia, or postmenopausal bleeding [1]. The exact
cause of endometrial polyps is unknown, but estrogenic
activity appears to play a crucial role in their pathogenesis
and growth [2]. Several molecular mechanisms have been
proposed to play a role in the development of endometrial

polyps. These include overexpression of endometrial aromatase, unbalanced activity between estrogen and progestin,
inhibition of apoptosis, certain gene mutations that favor
endometrial proliferation, and cellular mechanisms linked
with inflammation [3, 4].
Previous case series indicate that malignancy occurs
within 0% to 12.9% of endometrial polyps [4]. Although there
is no consensus in the literature on the exact risk factors
that are associated with malignant transformation of polyps,
most authors agree that the risk of malignancy is increased
with age and menopausal status and with the presence of
symptomatic bleeding [1, 2]. Larger endometrial polyps also
have been shown to be a risk factor for premalignant or
malignant pathology, with authors advocating a cut-off point
of 1.0 to 1.8 cm diameter as a risk factor [3–6].
Wang et al. retrospectively reviewed consecutive cases
of patients that underwent hysteroscopic removal of an
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endometrial polyp and correlated malignant and premalignant lesions to clinical risk factors [3]. Of the 766
patients, polyps were histologically benign (no atypia) in
96.21% of patients, hyperplasia with atypia was identified
in 3.26% of cases, and invasive endometrial carcinoma
was present in only 0.52% of patients. Independent variables that were significantly related to premalignant and
malignant polyps included polyp diameter greater than
1.0 cm, menopausal status, and abnormal uterine bleeding. In this report, hypertension, diabetes mellitus, body
mass index, and use of tamoxifen were not found to be
associated with the malignant transformation of polyps
[3].
Ferrazzi et al. compared the prevalence of hyperplasia
and malignancy in endometrial polyps among a cohort of
1,552 asymptomatic postmenopausal patients in comparison
to a similar cohort of 770 postmenopausal patients that presented with abnormal uterine bleeding [15]. The prevalence
of atypical hyperplastic polyps was 1.2% in asymptomatic
versus 2.2% in symptomatic patients (𝑃 < .005). One single
case of stage 1 grade 1 endometrial carcinoma was recorded
within a polyp with a mean diameter 4 cm in an asymptomatic patient. After multivariate analysis, diameter of the
polyps was the only variable significantly associated with an
abnormal histology (malignancy and atypical hyperplasia) in
asymptomatic women with an odds ratio of 6.9 (confidence
interval: 2.2–21.4) for polyps with mean diameter > 1.8 cm
[15].
Similarly, another retrospective review of 1,136 asymptomatic women that underwent hysteroscopic resection of an
endometrial polyp found that polyps with diameters greater
than 1.5 cm had hyperplasia rates of 14.8% compared with
7.7% in the group with smaller polyps (𝑃 < 0.5) [6]. Comparable to the above findings, Ben-Aire et al. assessed 430
women with endometrial polyps undergoing hysteroscopic
resection and found hyperplasia without atypia in 11.4% of
cases, hyperplasia with atypia in 3.3% of cases, and malignant
conditions in 3.0% of cases [5]. Older age, menopause status,
and polyps larger than 1.5 cm were associated with significant
premalignant or malignant changes [8]. Interestingly, the
presence of postmenopausal or irregular vaginal bleeding was
not a predictor of malignancy in this study [8].
Giant endometrial polyps larger than 4 cm in diameter are
exceedingly rare. Table 1 summarizes the management and
outcomes of reported cases of giant endometrial polyps in the
literature. The mean age of patients with giant endometrial
polyps was 66.6 years (range: 55–70). All of the reported
patients were postmenopausal. The most common presenting
symptom was vaginal bleeding. Of the reported cases, 58%
(7/12) were in association with use of a phytoestrogen or
selective estrogen receptor modulators such as tamoxifen or
raloxifene. In the report by Unal et al., the authors state that
the patient consumed a large amount of thyme, a known
phytoestrogen [13]. The six highest estrogen binding herbs are
soy, licorice, red clover, thyme, turmeric hops, and Verbena
[13].
Although not on exogenous drugs, the patient described
by Narin et al. had several risk factors similar to our patients,
including obesity, older age, and hypertension [10]. The
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patient described by Meena et al. did not present with postmenopausal bleeding and did not use hormones. However,
she had several risk factors including postmenopausal status,
obesity, diabetes mellitus, and hypertension. Similarly, the
patient in the case by Unal et al. did not report vaginal
bleeding; her polyp was discovered by an incidental CT
scan for complaints of lower back pain. Demographic details
were not provided in the report by Çil et al.; however, the
patient was of older age [1]. In addition to their menopausal
status, both of our patients have medical comorbidities that
may be risk factors for malignant transformation of polyps
including hypertension, obesity, and type 2 diabetes mellitus.
It is interesting to note that 8 of the 12 patients described
were of Turkish or Mediterranean origin. It is possible that
there are genetic, dietary, or ethnic factors related to the
development of large polyps; however, with such a small
incidence and limited reporting, no conclusions can be
inferred.
The rationale for removing polyps is to exclude malignancy and to relieve symptomatic vaginal bleeding. Management of small asymptomatic polyps may be conservative
with follow-up. However, conservative management should
be undertaken with caution in postmenopausal patients,
patients with any risk factors, or those with polyps measuring
greater than 1.0–1.5 cm in size, as there is increased risk for
atypical hyperplasia or malignancy [7, 15]. Risk factors for
malignancy differ among reports and populations; however,
larger size, advanced age, menopausal status, obesity, diabetes, arterial hypertension, and tamoxifen use have been
associated with malignancy.
Hysteroscopic polypectomy remains the mainstay of
evaluation and operative management of endometrial polyps
as the associated morbidity is minimal when compared
to a hysterectomy. Operative hysteroscopy allows for visualization of the entire uterine cavity. There are a variety
of methods practiced to remove polyps at hysteroscopy
(sharp scissors, electrosurgical techniques); however, there
are no comparative studies for these methods with regard
to efficacy. Therefore, the method of choice should be one
that is most familiar to the surgeon. Regardless of which
method is employed, removal of the entire polyp, including
complete excision of the polyp stalk, should be achieved.
Studies have indicated that removal of endometrial polyps
by blind curettage is unsuccessful in more than 50% of
attempts, and, in many cases, the removal is incomplete
[4]. Therefore, blind curettage should not be used as a
diagnostic or therapeutic intervention [4]. If malignancy is
found within the polyp, the patient should be referred to
a gynecological oncology specialist for further staging and
management.
It should be emphasized that the clinical implications and
oncogenic potential of large and giant endometrial polyps
are still unclear in the literature. Information is currently
derived from small studies, case series, and case reports.
The pathogenesis of endometrial polyps as well as factors
leading to oncogenesis is still being elucidated. Therefore,
with these limitations in knowledge, caution should be taken
when counseling patients that present with large or giant
endometrial polyps.

Tamoxifen
Raloxifene
No
Tamoxifen
Tamoxifen
Tamoxifen

Diameter 8 cm
4.5 × 4 × 5.2
12 × 6 × 5
10 × 6 × 3
9 × 7 × 4.5
8×6×3

74

63

66

55

Ünal et al. [13]
Antalya, Turkey
Meena et al. [14]
Delhi, India
van Staalduinen et
al.
New York, USA
(index cases)

Phytoestrogens
No
No
No

10 × 9
8.5 × 1.5
9.1 × 5.2 × 7.1
8×6×5

78

65

70

66

67

Tamoxifen

7.5 × 5.5 × 2.6

58

Catania, Italy

No

8×4×3

73

64

Associated drugs

Polyp size (cm)

Patient age

Caschetto et al. [12]

Report
Çil et al. [1]
Malatya, Turkey
Moon et al.
Busan, Republic of
Korea [7]
Nomikos et al. [8]
Piraeus, Greece
Kutuk and
Goksedef [9]
Amasya, Turkey
Narin et al. [10]
Adana, Turkey
Erdemoglu et al.
[11]
Isparta, Turkey

Management

Complex hyperplasia with
atypia
No hyperplasia, atypia, or
malignancy
No hyperplasia, atypia, or
malignancy
No hyperplasia, atypia, or
malignancy
Complex hyperplasia with
atypia
Simple hyperplasia, no
atypia
No hyperplasia, atypia, or
malignancy
Cystic hyperplasia without
atypia
No hyperplasia, atypia, or
malignancy
No hyperplasia, atypia, or
malignancy

Total abdominal
hysterectomy
Polypectomy under
ultrasound guidance
Total abdominal
hysterectomy, BSO
Extraction of mass under
general anesthesia
Total abdominal
hysterectomy, BSO
Total abdominal
hysterectomy, BSO
Total abdominal
hysterectomy

Polypectomy/hysteroscopy

Hysteroscopic polypectomy

Hysteroscopic polypectomy

No hyperplasia, atypia, or
malignancy

Pathology
No hyperplasia, atypia, or
malignancy

Total abdominal
hysterectomy

Hysteroscopic polypectomy

Table 1: Summary of reported cases of giant endometrial polyps.
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Data Availability
The data presented in article is available from the corresponding author upon request.

Consent
Consent was obtained for publication of case and images
from both patients and can be provided on request.
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